G

Giant Biogene Holding Co Ltd
HKEX:2367

Watchlist Manager
Giant Biogene Holding Co Ltd
HKEX:2367
Watchlist
Price: 36.4 HKD -4.96% Market Closed
Market Cap: 39B HKD

Giant Biogene Holding Co Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Giant Biogene Holding Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
Giant Biogene Holding Co Ltd
HKEX:2367
Cash & Cash Equivalents
ÂĄ4B
CAGR 3-Years
-17%
CAGR 5-Years
123%
CAGR 10-Years
N/A
Hengan International Group Company Ltd
HKEX:1044
Cash & Cash Equivalents
ÂĄ16.4B
CAGR 3-Years
-8%
CAGR 5-Years
4%
CAGR 10-Years
6%
Proya Cosmetics Co Ltd
SSE:603605
Cash & Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
Cash & Cash Equivalents
ÂĄ1.7B
CAGR 3-Years
-5%
CAGR 5-Years
27%
CAGR 10-Years
N/A
By-health Co Ltd
SZSE:300146
Cash & Cash Equivalents
ÂĄ2.6B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
5%
S
Shanghai Chicmax Cosmetic Co Ltd
HKEX:2145
Cash & Cash Equivalents
ÂĄ459.4m
CAGR 3-Years
47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Giant Biogene Holding Co Ltd
Glance View

Market Cap
39B HKD
Industry
Consumer products

In the bustling entrepreneurial landscape of China's Xi'an comes a formidable player in the skincare industry—Giant Biogene Holding Co Ltd. Founded in the early 2000s, the company quickly established itself as a pioneer in the biocosmetic field, underpinned by its commitment to leveraging cutting-edge biotechnologies. Positioned at the intersection of science and beauty, Giant Biogene concentrates on the research, production, and sale of bioactive skincare ingredients and products. These formulations, rich in proteins and polypeptides, target aspiring consumers eager to invest in beauty products that promise both efficacy and luxury. The company’s emphasis on integrating advanced bioengineering techniques with traditional Chinese medicinal practices has allowed it to carve out a distinct niche in the market, often emphasizing the scientific rigor and innovative spirit behind their product lines. Giant Biogene's revenue flows primarily from its comprehensive suite of skincare products, which are distributed through a variety of channels, including e-commerce platforms and retail partnerships. The company taps into the rising demand for premium anti-aging and skin-repair products in China's robust beauty market. This inclination towards advanced skincare solutions is largely fueled by an increasingly affluent middle class that places high value on personal care and appearance. The company further augments its revenue streams by developing proprietary formulas and licensing these innovative technologies to other skincare brands, thereby capitalizing on its formidable R&D capabilities. By maintaining a symbiotic relationship between its research endeavors and market strategy, Giant Biogene continues to thrive as a vanguard of scientific beauty solutions amid evolving consumer preferences.

Intrinsic Value
53.06 HKD
Undervaluation 31%
Intrinsic Value
Price
G

See Also

What is Giant Biogene Holding Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
4B CNY

Based on the financial report for Dec 31, 2024, Giant Biogene Holding Co Ltd's Cash & Cash Equivalents amounts to 4B CNY.

What is Giant Biogene Holding Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
123%

Over the last year, the Cash & Cash Equivalents growth was 61%. The average annual Cash & Cash Equivalents growth rates for Giant Biogene Holding Co Ltd have been -17% over the past three years , 123% over the past five years .

Back to Top